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3 Abstract  
Aim 
The purpose of this study was to evaluate the quality of surgical treatment in breast 
cancer in various aspects: treatment processes, surgical procedures, waiting times, day 
surgery and aesthetic and functional outcomes. In addition, a special emphasis was put 
on the surgical treatment of elderly breast cancer patients. 
Patients and methods 
In study I, the study population consisted of 1307 patients undergoing primary breast 
cancer surgery during 2010 in five hospitals in the Helsinki and Uusimaa Hospital 
District. The study population of study III included 637 patients receiving breast-
conserving treatment due to unilateral primary breast cancer during 2010 in the 
Helsinki and Uusimaa Hospital District. In study IV, 446 patients older than 80 years 
of age with primary breast cancer between January 2005 and December 2010 were 
included. In studies I–III, patients were retrospectively identified using electronic 
patient records using ICD-10 codes C50 and D05.1. The data were checked and 
completed with additional information from electronic patient records. Data on 
survival were collected from the Finnish Cancer Registry. In Study III, aesthetic and 
functional outcomes were evaluated with two separate questionnaires: the Breast 
Cancer Treatment Outcome Scale (BCTOS) and an author-created questionnaire. 
In Study II, 85 patients receiving breast-conserving surgery (BCS) and sentinel 
node biopsy (SNB) in a single breast cancer unit were prospectively included and 
randomised to day surgery or overnight stay. The patients and their spouses or other 
relatives received study questionnaires evaluating their perceptions of day surgery and 
physical and psychological recovery within discharge.   
Results  
In Study I, the final rate of BCS was surprisingly low (51%), unaffected by hospital 
volume (p=0.781). Oncoplastic resection (33% of BCS in a high-volume unit vs. 0–
12% in lower-volume units) and immediate breast reconstruction (IBR) (11–20% of 
all mastectomies in high-volume units vs. 0% in lower-volume units) were performed 
more often in high-volume units (p<0.001). The quality of axillary surgery varied with 
unit size; the rate of axillary lymph node dissection (ALND) in node-negative patients 
Abstract 
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was higher at 14–27% in low-volume hospitals compared to 5–8% in high-volume 
hospitals (p=0.009). The median waiting time for primary surgery was 24 days, 
significantly prolonged by additional magnetic resonance imaging (MRI) (34 days; 
p<0.001) and diagnostic biopsies (37 days; p<0.001). Low-volume hospitals provided 
primary surgery significantly faster (15–17 days vs. 26–27 days; p<0.001). The 
median waiting time from the primary operation to the initiation of any adjuvant 
treatment was 47 days. Wait times for the initiation of adjuvant treatment were 
significantly affected by the type of primary surgery and the number of cancer 
operations, that is, immediate breast reconstruction (54 days; p=0.011) and re-
excisions (57 days on patients with two cancer operations; p<0.001), naturally.  
In study II, the day surgical discharge rate was lower than expected; 18 (47%) 
patients randomised to day surgery were discharged the same day. The most common 
reason for overnight hospital stay was ALND, which occurred in 9 (24%) patients. 
Questionnaire results on perceptions of day surgery were analysed both according to 
randomisation and actual treatment groups. Patients in both groups had rather similar 
experiences on the first postoperative day. Also, spouses’ or relatives’ perceptions 
after discharge were similar in both groups.  
In study III, the questionnaires concerning aesthetic and functional outcomes after 
BCS were returned by 379 (59%) patients. Of these, 293 (77%) had conventional 
breast resection and 86 (23%) had an oncoplastic resection. Patients in the oncoplastic 
resection group had significantly larger tumour diameters (16.0 mm vs. 12.0 mm; 
p<0.001), more often multifocal tumours (12% vs. 5%; p=0.032) and node-positive 
cancer (30% vs. 22%; p=0.029). Accordingly, resection specimens were larger (97 g 
vs. 61 g; p<0.001). In the oncoplastic resection group, lower quadrant tumour 
localisation (25% vs. 19%; p=0.007) was more frequent. ALND was performed 
significantly more often in the oncoplastic resection group (p=0.007), reflecting a 
difference in nodal status between the groups. There was no statistical difference 
between the groups as regards receiving radiotherapy (RT) and those receiving tumour 
bed boosters. In univariate analysis, larger tumour diameter (p=0.033), multifocality 
(p=0.022), weight of the resection specimen (p<0.001) and oncoplastic surgery 
(p<0.001) were predicting a poor aesthetic outcome when all patients were included. 
In study IV, 401 (90%) patients received surgery. The median follow-up time was 
52 months. The overall survival (OS) of patients was significantly better in the surgical 
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treatment group, five-year OS being 50.6% in the surgical treatment group and 15.2% 
in the non-surgical treatment group (p<0.001). Also, breast cancer-specific survival 
(BCSS) was significantly better in patients with surgery, five-year BCSS being 82.0% 
in patients with surgery and 56.0% in patients without (p<0.001). Altogether, 122 
(30%) patients in the surgical treatment group died within three years of surgery.   
Conclusions 
The quality of preoperative diagnostics greatly impacts the timely treatment of breast 
cancer. The positive impact of high-volume hospitals becomes evident when novel or 
skill-demanding surgical techniques like oncoplastic surgery and breast reconstruction 
are used. Day surgery is feasible in breast surgery after BCS and SNB. Overall patient 
satisfaction after BCS is high. Conventional resection provides good aesthetic 
outcomes in appropriately selected patients. Oncoplastic resection enables BCT in 
patients with larger, multifocal tumours with a favourable aesthetic outcome. In 
elderly breast cancer patients, OS and BCSS were better in surgically treated patients.  





Worldwide, breast cancer is the most common cancer in women and the leading cause 
of cancer death. In Finland, the annual incidence of breast cancer was 5161 in 2015.  
However, breast cancer survival in Finland is one of the highest in Europe. According 
to the Finnish Cancer Registry, the predicted breast cancer-specific five-year survival 
rate from 2012 to 2014 is 91% and the ten-year survival rate is 85%. The age-adjusted 
breast cancer mortality rate has decreased by 30% since 1990 and was 27/100 000 in 
2014. 
The aim of breast cancer surgery is to provide excellent oncological outcomes with 
minimal risk of local and regional recurrences. Quality of life (QoL) is the second 
most important aim in breast cancer treatment. Today’s breast cancer treatment with 
an effective screening program, improved diagnostics, better quality of surgery and 
more effective adjuvant treatments has resulted in increased breast cancer survival.  
The significance of QoL after breast cancer treatment is thereby extremely important. 
To achieve better oncological outcomes and QoL, timely treatment and high-
quality surgery are crucial. Delays in adjuvant treatment are associated with worse 
breast cancer outcomes (Gagliato et al. 2014, Richards et al. 1999); a four-week delay 
in systemic adjuvant treatment increases the risk for recurrence by 16% and mortality 
by 15% (Yu et al. 2013). Furthermore, many surgery-related factors may delay the 
initiation of adjuvant treatments and thus increase recurrence risk. Although many 
factors associated with delays in breast cancer treatment have been identified, the 
impact of organisational factors is also recognised and remains to be evaluated 
(Liederbach et al. 2015).   
Both aesthetic and functional outcomes after breast cancer surgery influence QoL 
(Mansel et al. 2006, Heil et al. 2010). Therefore, an aesthetic outcome after BCS is an 
important goal (Heil et al. 2011, Santos et al. 2015). Several factors are associated 
with poor aesthetic outcome: central, medial or inferior tumour locations, larger 
tumour size, larger specimen volume, reoperation due to positive margins, radiation 
therapy and radiation boost (Foersteling et al. 2014, Hennings et al. 2015, Heil et al. 
2012, Immink et al. 2012, Vrieling et al. 2000). Recognising the negative effects of 
poor aesthetic outcomes on QoL has facilitated the development of various oncoplastic 
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techniques. The oncoplastic approach also enables BCS for patients with larger and 
multifocal tumours without compromising aesthetic and functional outcomes. 
Previous studies implicate that oncoplastic surgery provides better aesthetic outcomes 
than conventional wide local excision (Losken et al. 2014). However, evaluation of 
aesthetic outcomes after breast cancer surgery lacks a gold standard, and methodology 
varies greatly (Chen et al. 2010). Further research is needed to establish the role of 
oncoplastic surgery in breast-conserving treatment.  
However, the benefits of improved breast cancer treatment and increasing survival 
are not distributed equally in the breast cancer patient population. In elderly patients, 
breast cancer treatment guidelines are less often followed (van de Water et al. 2012, 
Kiderlen et al. 2015, Angarita et al. 2015, Shumway et al. 2017). Accordingly, not 
only OS but also BCSS have been inferior when compared to younger breast cancer 
patients. This is important since the number of elderly breast cancer patients is 
increasing due to ageing of the population. Altogether, 3179 women aged 80 years 
and older were diagnosed with primary breast cancer in Finland between 2011 and 
2015 (Finnish Cancer Registry).  
The impact of adjuvant radiotherapy (RT) on survival and local recurrences has 
been investigated (Matuchek et al. 2017, EBCTCG 2011), but there is less evidence 
regarding the benefits of surgery on local disease control and survival in elderly breast 
cancer patients (Hamaker et al. 2013). However, local disease control markedly affects 
QoL. Moreover, QoL is extremely important in elderly patients with limited life 
expectancy. Individualising treatment on the heterogeneous elderly breast cancer 
patient population is highly important.   
The aim of the present study was to evaluate the quality of surgical treatment and 
the impact of surgery on aesthetic outcomes and delays in breast cancer treatment.  
The feasibility of day surgery in breast cancer was also investigated. A further aim 
was to evaluate surgical treatment and prognosis of elderly patients over 80 years of 
age.  
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5 Review of the literature 
5.1 Breast cancer incidence and survival  
Breast cancer is the most common cancer in women worldwide. In Finland, breast 
cancer incidence is among the highest in the world; the annual incidence in 2015 was 
5161 and the age-adjusted incidence 177/100 000. The age-adjusted breast cancer 
incidence has increased by 2.3 times in Finland during the past 40 years (Finnish 
Cancer Registry, 2018).  
Several factors have been identified to increase breast cancer incidence: menarche 
is starting earlier, childlessness is more frequent, and first pregnancies are at an older 
age. Hormone replacement therapy increases the risk of breast cancer, especially if 
used over five years’ time. Obesity and alcohol use are also known to increase breast 
cancer incidence. Overdiagnosis caused by breast cancer screening may further 
increase the incidence slightly (Berry et al. 2005, Bleyer et al. 2012, Miller et al. 2014). 
In elderly patients, breast cancer incidence is increasing due to ageing of the 
population. Breast cancer incidence in elderly patients in Finland is high: from 2011 
to 2015, the incidence was 221/100 000 in women from 80 to 85 years and 247/100 
000 in those 85 years and older. Altogether, 3179 women aged 80 years and older 
were diagnosed with primary breast cancer in Finland between 2011 and 2015 (Finnish 
Cancer Registry).   
Worldwide, breast cancer is the most common cause of cancer death in women. In 
Finland, breast cancer survival is one of the highest in Europe. According to the 
Finnish Cancer Registry, the predicted breast cancer-specific five-year survival rate 
from 2012 to 2014 is 91%, and the ten-year survival rate is 85%. The age-adjusted 
breast cancer mortality rate has decreased by 30% since 1990 and was 27/100 000 in 
2014. The high survival rate is due to early detection of breast cancer, particularly in 
the biannual screening program for women between 50 and 69 years of age, and 




5.2 Diagnosis and staging of breast cancer 
Triple diagnosis is the gold standard in breast cancer diagnosis. The triple diagnostic 
approach consists of a clinical examination, breast imaging and a core needle biopsy.  
Breast imaging usually consists of mammography combined with breast and axillary 
ultrasound. Breast magnetic resonance imaging (MRI) can be used in selected cases, 
for example in invasive lobular cancer or in women with dense breasts. Breast MRI is 
the most sensitive imaging modality in breast cancer diagnostics, with over 90% 
sensitivity (Berg et al. 2004). However, false-positive findings in MRI occur in 10–
15% of patients, leading to additional needle biopsies. Breast imaging should be 
conducted prior to biopsy, since haematoma may interfere with image interpretation.  
If any component of the triple diagnosis is suspiciuos of malignancy, a repeated core 
needle biopsy or surgical biopsy should be conducted.   
Core needle biopsy is taken from the suspicious lesion in the breast, frequently 
guided by ultrasound. Sometimes, mammography or MRI are used in biopsy guidance. 
Core needle biopsy usually provides a tissue sample that allows for histological typing 
of the cancer and enables determination of tumour oestrogen, progesterone and human 
epidermal growth factor receptor 2 (HER2) status as well as Ki-67 expression. The 
diagnostic accuracy of fine needle aspiration cytology is inferior when compared to 
core needle biopsy (Hukkinen et al. 2008). 
Axillary nodal status is the single most important prognostic factor in breast 
cancer. Axillary ultrasound is performed as part of the diagnosis, and fine needle 
biopsy is taken from suspicious nodes. Specificity of a positive ultrasound and needle 
biopsy is as high as 98% with 80% sensitivity (Houssami et al. 2011). Axillary staging 
with ultrasound and needle biopsy can optimise surgical treatment in node-positive 
patients by utilising a single axillary procedure, the gold standard currently being 
ALND. In patients with node-negative breast cancer, SNB is the gold standard in nodal 
staging.   
For patients at high and intermediate risk of distant relapses, imaging the chest, 
abdomen and bone is recommended before administering systemic treatments. This is 
mainly done through computed tomography (CT) of the chest, CT or ultrasound of the 
abdomen and isotope bone scintigraphy. Positron emission tomography (PET) may 
reveal regional or distant metastases not detected by other methods and may thus be 
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helpful when findings of commonly used imaging are unclear. PET may also show an 
earlier response to systemic therapy.   
5.3 Multidisciplinary treatment in breast cancer 
The management of early breast cancer involves several medical specialities. 
Therefore, treatment is best performed with a specialist multidisciplinary team to 
ensure optimal outcomes in terms of patient survival and QoL. The treatment of early 
breast cancer usually starts with surgery. The postoperative multidisciplinary meeting 
gives adjuvant treatment recommendations based on treatment guidelines and patient 
and tumour characteristics. If adjuvant chemotherapy is recommended, it is initiated 
postoperatively within four to six weeks. Endocrine treatment and/or radiotherapy 
follow chemotherapy. In Finland, neoadjuvant systemic therapy has been generally 
used in inflammatory breast cancer and in locally advanced disease to facilitate 
surgery. Neoadjuvant treatment also enables effective early treatment in aggressive 
breast cancer (i.e. HER2 positive and triple negative disease). In addition, neoadjuvant 
treatment is also currently used to facilitate BCS by tumour downsizing.   
The multidisciplinary meeting is an important step in coordinating breast cancer 
treatment. The multidisciplinary team consists of the breast surgeon, clinical 
oncologist, pathologist, radiologist and breast cancer nurse. The plastic surgeon, 
physiotherapist and research nurse can also take part in multidisciplinary meetings. 
Multidisciplinary teams are noted to make better clinical decisions, evidence-based 
practice and improved quality of treatment (Biganzoli et al. 2017). The 
multidisciplinary meetings also serve teaching purposes.   
 
5.4 Surgical treatment 
Aims of surgical treatment  
The aim of surgical treatment is to minimise the risk of local and regional recurrences 
and thereby increase survival. Surgery also enables pathological assessment and 
staging of the tumour, facilitating tailoring the adjuvant treatments and providing 
information regarding prognosis.   
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The development of diagnosis and adjuvant treatments has markedly improved 
breast cancer survival, thus emphasising the value of QoL. Both functional and 
aesthetic outcomes after surgery influence QoL (Heil et al. 2010, Santos et al. 2015). 
Therefore, an important aim of surgery is tailoring the treatment individually by 
accounting for both local-regional disease control and aesthetic and functional 
outcomes. 
Today, breast cancer surgery is markedly more conservative than ever before with 
equal or even better oncological outcomes. Not only physical recovery but also 
psychological and social recovery after breast cancer surgery are important. BCS itself 
has possibly reduced both early and late psychological implications of the disease 
(Moyer et al. 1997, Wapnir et al. 1999). Accordingly, hospitalisation after breast 
cancer surgery has decreased, and even day surgery is possible.  However, the patient’s 
preferences and perceptions regarding day surgery have not been widely evaluated 
(Marla et al. 2009, Bonnema et al. 1998). 
Mastectomy 
Radical mastectomy was described in 1882 by Halsted and by Meyer in 1884. It 
consisted of removing the breast glandular tissue and in addition, the pectoralis major 
and minor muscles with axillary lymph nodes. In 1932, D.H. Patey first performed a 
mastectomy that preserved the pectoralis major muscle. Patey and W.H. Dyson 
described the technique in their 1948 article. In 1972, JL Madden published the 
mastectomy technique for saving both pectoral muscles.   
Mastectomy was the standard treatment for all breast cancer patients until the 
1980s. Today, it is still recommended for patients with tumours too large for breast 
conservation with acceptable aesthetic outcomes or is performed upon patient request. 
Mastectomy is also indicated if RT is contraindicated after BCS, as in patients with 
earlier RT on the same field. In inflammatory breast cancer, mastectomy is always 
performed after neoadjuvant treatment. Risk-reducing mastectomy can be performed 
in patients with a genetic predisposition to breast cancer, like BRCA1 and BRCA2 
mutation carriers. However, even in gene mutation carriers, if breast cancer is already 
diagnosed, tumour biology and cancer prognosis define the treatment and extent of the 
surgery.  
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Breast-conserving surgery 
In the 1930s, Finnish professor Sakari Mustakallio started performing breast-
conserving surgery. However, it was not until the 1970s that this more conservative 
form of surgery began to be more widely accepted. When the randomised trials of 
professors Umberto Veronesi and Bernard Fisher in the 1980s reported similar 
survival in patients treated by BCS combined with either radiation therapy or 
mastectomy, breast conservation became a standard treatment option in breast cancer 
surgery (Fisher et al. 1985, Veronesi et al. 1981).   
Indications of BCS have extended since early on. It was initially recommended 
only to patients with small (<2 cm) unifocal tumours with a low risk of lymph node 
metastases. Since then, breast conservation has shown to be feasible and safe in larger 
and even multifocal tumours with axillary metastases when tumour-free margins are 
achieved (Gentilini et al. 2007). The consensus regarding acceptable tumour-free 
margins has also changed over time. Currently accepted are the tumour-free resection 
margin (i.e., no tumour on the ink) in invasive cancer and the 2 mm margin in ductal 
carcinoma in situ (DCIS). Nowadays, the rate of BCS is considered a central quality 
indicator in breast cancer treatment.  
Contraindications of BCS are a large tumour-breast ratio, contraindication of 
radiotherapy or poor co-operation regarding radiotherapy. However, in elderly 
patients with comorbidities, radiotherapy can sometimes be omitted after BCS 
(EBCTCG 2005b).  
In BCS, the tumour is resected with acceptable tumour-free margins to ensure 
oncological safety. Non-palpable tumours are preoperatively marked with a guide 
wire, radioactive isotope or radioactive seed utilising proper imaging modalities. The 
resection of breast tissue is performed with adequate mobilisation and closure of tissue 
to reach the best possible aesthetic outcome.  
Neoadjuvant treatment is an option for patients who desire breast conservation, but 
their tumour size is too large. It can be considered especially for patients with HER2-
positive or triple-negative breast cancer. Neoadjuvant treatment has equivalent overall 
survival outcomes with adjuvant therapies, but BCS can be performed more often after 
neoadjuvant treatment because of tumour downsizing (Fisher et al. 1998, van der Hage 
et al. 2007). Recent meta-analyses from EBCTCG noted an increased risk of local 
recurrences after neoadjuvant treatment (Biganzoli et al. 2017). However, the results 
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might have been affected by subgroups of patients without any surgery after 
neoadjuvant treatment due to clinical complete response. Not surprisingly, these 
patients had more local recurrences at their follow-up. Interestingly, recent studies 
suggest that despite the increased use of neoadjuvant therapy, conversion from a 
planned mastectomy to breast conservation after neoadjuvant therapy has not always 
been adopted. A recommendation for mastectomy before neoadjuvant therapy, 
combined with the option of reconstructive surgery, may in fact drive more extensive 
surgery, that is, risk-reducing contralateral mastectomy and bilateral IBR. A study by 
Karakatsanis et al. (2018) showed that breast surgery performed after neoadjuvant 
therapy does not reflect tumour response. However, even after complete pathological 
response, the original extent and possible multifocality of the tumour should be kept 
in mind when planning surgery after neoadjuvant treatment. 
Oncoplastic surgery 
A satisfactory aesthetic outcome is the second most important goal in BCS after 
oncological safety. However, unsatisfactory cosmetic outcomes are still observed after 
conventional resection in up to 20–40% of patients (Haloua et al. 2013, Dahlback et 
al. 2016). Several factors associated with poor aesthetic outcomes have been 
identified: central, medial or inferior tumour locations, larger tumour size, larger 
specimen volume, reoperation due to positive margins, radiation therapy and radiation 
boost (Foesterling et al. 2014, Hennings et al. 2015, Heil et al. 2012, Immink et al. 
2012, Vrieling et al. 2000).  
Since the 2000s, numerous oncoplastic techniques have been developed to 
improve aesthetic outcomes and enable breast conservation in patients with larger 
tumour-breast ratios or with tumours in challenging locations. In oncoplasty, breast 
tissue is reshaped, replaced or rearranged after tumour removal to produce a better 
aesthetic outcome (Clough et al. 2010). Oncologic safety of oncoplastic breast-
conserving surgery seems to be as good as after conventional wide local excision 
(Clough et al. 2017).   
Although oncoplastic surgery includes also IBR, a direct comparison between 
these types of breast cancer operations is seldom made. Previous studies have 
demonstrated that with oncoplastic surgery, selected patients could achieve breast 
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conservation and avoid mastectomy and IBR with similar or even better psychosocial 
and aesthetic outcomes as well as QoL compared to IBR (Kelsall et al. 2017, 
Nicholson et al. 2007, Howes et al. 2016).   
Aesthetic outcomes after breast-conserving surgery 
Evaluating aesthetic outcomes is lacking in standardised methods. A wide variation in 
the methodology makes comparing different study results difficult. Objective 
evaluation methods are based on either direct clinical evaluation or on the evaluation 
of photographs. Objective methods are costly, but at least some are reproducible 
(Cardoso et al. 2007). When evaluating treatment outcomes, patient self-evaluation is 
a valuable method since the subjective experience is central in the assessment of QoL 
(Stanton et al. 2001, Heil et al. 2010). However, even self-evaluation instruments vary 
from a single question to validated multi-item questionnaires. Previous studies also 
show that patient-reported aesthetic outcome questionnaires may provide more 
favourable aesthetic outcomes than objective aesthetic outcome measurements (Heil 
et al. 2011, Santos et al. 2015).   
The most appropriate time to evaluate aesthetic outcomes after BCT and RT is not 
clear (Vrieiling et al. 2000, Haloua et al. 2013). Evaluating too soon after surgery and 
RT may produce falsely good results because of swelling after radiotherapy. Fibrosis 
and retraction after RT can increase up to three years (Immink et al. 2012).   
Breast reconstruction  
Mastectomy without reconstruction results in inferior QoL. Breast reconstruction 
following mastectomy has benefits in body image, self-esteem and sexuality, leading 
to a better QoL (Elsahir et al. 2013). Breast reconstruction after mastectomy is one 
quality indicator in breast cancer treatment, and every patient receiving mastectomy 
should be informed about breast reconstruction.   
Breast reconstruction can be performed immediately with mastectomy or in a 
delayed fashion after adjuvant treatments. It is important to remember that 
mastectomy with IBR is a more extensive operation than mastectomy alone. Breast 
reconstruction has risks: wound healing problems, infection, anastomosis problems in 
microvascular settings, thromboembolic complications and longer hospital stays. 
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After IBR, adjuvant treatments may be delayed due to healing problems, possibly 
negatively affecting oncological results (Vandergrift et al. 2013). In patients with a 
high risk of recurrence, IBR should be carefully considered to prevent delays in 
adjuvant treatments.   
 Radiation of the reconstructed breast is known to lead to suboptimal aesthetic 
outcomes, fat necrosis, fibrotic changes and capsular contracture after implant-based 
reconstructions. If the patient needs post-mastectomy RT, delayed breast 
reconstruction should be considered instead of  IBR. IBR is ideal for low-risk invasive 
cancer patients or for patients with DCIS. Delayed breast reconstruction is usually 
performed one to three years after mastectomy. If the patient is uncertain about breast 
reconstruction at the time of their diagnosis, delayed breast reconstruction is a better 
option. 
Nowadays, multiple techniques for breast reconstruction are available. The aim of 
breast reconstruction is to create a natural appearance of the reconstructed breast with 
the simplest possible technique. The main reconstruction options are prosthesis 
reconstruction and autologous tissue reconstruction or a combination of the two.  
Several local, pedicular and microvascular flaps are available for breast 
reconstruction. The most common autologous reconstruction options are the pedicular 
latissimus dorsi flap and microvascular flaps of the lower abdominal region.   
Axillary lymph node dissection 
Surgical treatment of breast cancer consists not only of the breast surgery but also of 
axillary surgery. ALND was the gold standard in axillary staging for decades. A 
diagnostic ALND includes Berg levels I and II (lymph nodes lateral to and underneath 
the pectoralis minor muscle). Berg level III includes lymph nodes medial to the 
pectoralis minor muscle and should be included in dissection, when the patient has 
overt axillary metastases. The accuracy of axillary nodal staging is dependent on the 
number of examined nodes (Schaapveld et al. 2004), and ALND has been considered 
accurate if at least ten lymph nodes have been examined. The number of examined 
nodes is dependent both on quality of surgery and on pathology. ALND is therapeutic 
only in node-positive patients, and until recently, it has been routine in sentinel node–
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positive patients. Axillary recurrences are rare after ALND, at 0.6–1.0% over a five-
year follow up (Gentilini et al. 2007, Siponen et al. 2012).   
ALND leads to acute and long-term morbidity such as upper arm lymphoedema, 
pain, numbness, loss of strength and impaired range of motion in the involved arm 
(Mansel et al. 2006). These symptoms affect 20–80% of women who undergo ALND 
and axillary RT.   
Sentinel lymph node biopsy 
Today, breast cancers are detected earlier without axillary involvement due to 
mammography screening and improved diagnostics in general. With clinically node-
negative patients, morbidity after ALND compromises QoL. Therefore, less invasive 
but equally accurate axillary staging methods have been sought. Different imaging 
modalities are not sensitive enough to exclude axillary lymph node metastases, 
although axillary ultrasound in combination with needle biopsy can detect positive 
axillary nodes in approximately 80% of node-positive patients (Houssami et al. 2011).   
During the 1990s, SNB was introduced in nodal staging in breast cancer (Giuliano 
et al. 1996). The safety of SNB was further proved in randomised trials, the first of 
which was published in 2003 (Veronesi et al. 2003). SNB became the standard of care 
after innumerable validation studies showed an average false negative rate of 7.3% 
(Kim et al. 2006). Originally, SNB was indicated in invasive T1 and small T2 
clinically node-negative tumours. Nowadays, SNB is also indicated in larger tumours 
whenever they are clinically node-negative.   
In pure DCIS nodal staging is not needed. However, in 13 to 35 % of cases with 
preoperative DCIS diagnoses invasive breast cancer is detected in final pathological 
examination of surgical specimen.  In these cases, SNB can be performed as a second 
operation after breast conservation. However, SNB is performed in DCIS patients 
undergoing mastectomy.   
Numerous studies have clearly proven lower postoperative morbidity after SNB 
when compared with ALND (Mansel et al. 2006, Galimberti et al. 2013, Rönkä et al. 
2005, Leidenius et al. 2005). After ALND, both short-term and long-term morbidity 
are more common than after SNB (Haid et al. 2002, Rönkä et al. 2005). The 
ALMANAC study showed better QoL after SNB than ALND (Mansel et al. 2006). 
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The number of ALND performed in node-negative patients should remain low and is 
considered a quality indicator in breast cancer treatment.  
Until recently, ALND has been the routine treatment after positive SNB. However, 
previous studies have demonstrated only about a 40% rate of additional metastatic 
nodes in ALND after positive SNB (van la Parra et al. 2011). In addition, a few 
randomised trials have evaluated the role of ALND in the treatment of sentinel node–
positive patients. ACOSOG Z0011 was a prospective randomised controlled trial 
evaluating the need for completion ALND after positive SNB (Giuliano et al. 2011). 
In this study, patients with micro- or macrometastases were randomised either to 
ALND or observation only after the detection of one or two positive lymph nodes in 
SNB. In the ACOSOG Z0011 trial, no differences in local or regional recurrence rates 
or in survival were observed in the 9.25-year follow-up (Giuliano et al. 2016). In the 
IBCSG 23-01 trial, patients with micrometastases (≤2mm) were randomised to ALND 
or no ALND with no difference in five-year disease free survival (Galimberti et al. 
2013). Another study, AMAROS, compared ALND with axillary RT after a positive 
SNB (Straver et al. 2014). This study concludes that after a positive SNB, ALND and 
axillary radiotherapy provide excellent and comparable axillary control for patients 
with T1–2 primary breast cancer and no palpable lymphadenopathy.  
Results of recent randomised trials have already changed treatment guidelines 
throughout the world. In Finland, ALND is no longer recommended in patients with 
ITC or micrometastases in SNB. In macrometastatic findings in SNB, the Finnish 
national treatment guideline discourages replacing ALND routinely with axillary RT 
since the follow-up period of the AMAROS study is limited concerning disease-free 
survival.  
5.5 Systemic adjuvant treatment   
Systemic adjuvant treatment reduces the risk of breast cancer recurrence and improves 
survival. Without any systemic adjuvant treatment, ten-year recurrence-free survival 
has been 65% in node-negative patients and 43% in node-positive patients (EBCTCG 
2011). Systemic adjuvant treatment is individually planned based on tumour and 
patient characteristics. Adjuvant chemotherapy reduces the recurrence rate in all 
biological subtypes of breast cancer. In EBCTCG meta-analyses (2005), the 
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anthracycline-based chemotherapy regimens produced relative mortality reductions of 
20–38% on average. Endocrine treatment for ER-positive patients adds a further 
relative mortality reduction of 31%. However, comorbidities and advanced age may 
restrict chemotherapy use. Usually, six cycles of adjuvant chemotherapy are 
administered prior to radiotherapy. In HER2-positive patients, trastuzumab treatment 
is initiated simultaneously with chemotherapy. The duration of trastuzumab treatment 
is usually one year.  
According to the Finnish National Breast Cancer Treatment Guideline, an 
estimated recurrence rate of over 10% in ten years is considered an indication for 
systemic adjuvant treatment. Histological tumour type and stage, nodal status, 
oestrogen and progesterone receptor status, HER2 amplification status and 
proliferation index are cancer-related factors that affect treatment decisions. Patient 
age, comorbidities and general conditions are evaluated as well.  
Timely treatment without delays is considered a core quality indicator in breast 
cancer treatment (Del Turco et al. 2010). No consensus exists on the optimal time 
interval between surgery and adjuvant treatment. The Finnish Ministry of Social 
Affairs and Health has recommended that the time interval from surgery to the 
initiation of adjuvant treatment should be from four to six weeks. Delays in adjuvant 
treatment are associated with worse breast cancer outcomes in stage III breast cancer 
and especially in aggressive HER2 positive or triple negative disease (Gagliato et al. 
2014, Richards et al. 1999); a four-week delay in systemic adjuvant treatment 
increases the relative risk of  recurrence by 16% and mortality by 15% (Yu et al. 2013). 
Furthermore, many surgery-related factors such as number of cancer operations and 
complications may delay the initiation of adjuvant treatments and thus increase the 
recurrence risk.   
In oestrogen receptor (ER)-positive breast cancer, endocrine treatment reduces the 
relative risk for recurrence by 50% and mortality by 30% (EBCTCG 2005a, 2005b). 
For ER-positive disease, endocrine treatment reduces the annual breast cancer death 
rate by 31%, respectively. Systemic endocrine treatment is considered in all patients 
with hormone receptor–positive cancer. Endocrine treatment is usually initiated after 
chemotherapy and simultaneously with RT. Tamoxifen and aromatase inhibitors are 
used depending on menopausal status. In premenopausal patients, ovarian suppression 
with tamoxifen or exemestane may be used according to the risk of recurrence. Recent 
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meta-analyses showed that using an aromatase inhibitor for five years reduces ten-
year breast cancer mortality rates by about 15% compared with five years of 
tamoxifen, hence by about 40% proportionately compared with no endocrine 
treatment (EBCTCG 2015). Prolonged endocrine treatment for up to ten years should 
be considered for patients with a high risk of recurrence. 
5.6 Radiotherapy 
Whole-breast RT is recommended for all patients after BCS. The impact of adjuvant 
RT on survival and local recurrences is well defined. RT decreases local recurrences 
by 65–75%, prolongs disease-free survival and reduces breast cancer mortality. After 
a 15-year follow-up, about one breast cancer death is avoided for every four local 
recurrences avoided. RT also reduces 15-year overall mortality (EBCTCG 2000, 
2005). A radiation booster to the resection site is recommended for high-risk patients 
as it decreases the risk of local recurrences but does not affect survival (Kindts et al. 
2017). The radiation booster may have a negative impact on aesthetics after breast 
conservation, however (Immink et al. 2012, Vrieling et al. 2000).   
In elderly patients, RT after BCS does not provide a survival benefit but lowers 
the risk of local recurrence (EBCTCG 2005, Matuschek et al. 2017). In this elderly 
patient group, RT-induced adverse effects and negative impacts on QoL should be 
understood when planning treatment. However, mastectomy should not be routine in 
elderly patients if adjuvant RT after BCS is not possible.   
RT after mastectomy decreases the risks of recurrence and breast cancer death in 
all patients with node-positive cancer. In these patients, RT after mastectomy provided 
a significant decrease in the 10-year risk of local-regional recurrence (8.1% vs. 26.0%; 
p<0.00001). RT also significantly decreased 20-year breast cancer mortality (58.3% 
vs. 66.4%; p=0.001). However, in patients with node-negative cancer, RT improved 
neither local-regional disease control nor BCSS (EBCTCG 2014).   
Based on these results, RT is recommended for mastectomy patients with node-
positive disease. RT is also recommended in node-negative T3 and T4 tumours and 
can be considered even in T2 tumours if specific risk factors exist.  
The RT of nodal regions (axillary, parasternal and supraclavicular regions) is 
indicated in patients with nodal involvement. The treatment of nodal regions is 
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individually based on tumour size, biology, number of involved nodes and type of 
axillary surgery. Axillary surgery in breast cancer treatment is evolving rapidly, and a 
more conservative approach is adopted: the number of patients with ALND is 
decreasing. Naturally, this reflects in the planning of nodal radiotherapy.   
5.7 Breast cancer in the elderly 
Breast cancer in the elderly differs from the disease in younger women both in the 
diagnosis stage and in biological tumour characteristics. The biological features of 
breast cancer are often more favourable, with lower-grade tumours and more frequent 
oestrogen receptor expression (Diab et al. 2000). This is counterbalanced by larger 
tumours as well as higher rates of locally advanced and metastatic disease in diagnoses 
of older women (Bastiaannet et al. 2010, Gennari et al. 2004). These differences may 
be explained by missing screenings in older women and less breast cancer awareness.   
The definition of an elderly patient varies greatly in the literature, ranging from 
65-year-olds to over 80-year-olds. Naturally, this makes interpreting and comparing 
the results difficult. Moreover, in elderly patients, chronological age does not always 
correlate with biological age. Functionality and QoL may persist at the same level for 
years despite several comorbidities and frailty. Therefore, evaluating life expectancy 
even in the presence of serious comorbidities is difficult. Geriatric assessment tools 
may provide additional useful information for decision-making. Nevertheless, 
usability of geriatric assessment tools in clinical practice is suboptimal and needs 
further development (Huisman et al. 2017, Parks et al. 2015, Thomas et al. 2017).    
Treatment guidelines are followed less often in elderly breast cancer patients, 
leading to under-treatment (van de Water et al. 2012, Kiderlen et al. 2015, Angarita et 
al. 2015, Shumway et al. 2017, Biganzoli et al. 2017). This can partly be explained by 
comorbidities and the frailty of older patients, preventing the use of adjuvant 
treatments, chemotherapy particularly. Accordingly, not only OS but also BCSS are 
inferior when compared to younger breast cancer patients. Naturally, OS is worse in 
older women with breast cancer due to other causes of death. On the other hand, BCSS 
in the elderly is also decreased, implicating the undertreatment of breast cancer. 
Tailoring breast cancer treatment without compromising survival or QoL is a 
significant clinical challenge. Local control influences QoL and is thus of high 
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importance in the elderly. However, physicians’ nihilistic attitudes may also affect 
treatment decisions.   
Local treatment 
Local treatment, that is, RT and especially surgery, is the cornerstone of treatment in 
early breast cancer, even among the elderly. One of the most important aims of breast 
cancer treatment in the elderly is to provide local disease control. However, elderly 
patients receive surgery markedly less often than younger patients, and over time, it 
has become more common to omit surgery in older women (Kiderlen et al. 2017). On 
the other hand, surgical procedures in the elderly have often been more extensive; 
mastectomy and ALND are performed instead of BCS and SNB (Sierink et al. 2014, 
Eaker et al. 2006, Kiderlen et al. 2015). Previous trials have shown that RT after BCS 
does not provide survival benefits but lowers the risk of local recurrence in elderly 
women (Hughes et al. 2013, EBCTCB 2005). Adverse effects of RT may also be more 
common in the elderly population.   
Systemic adjuvant treatment 
With increasing age, a decrease in provision of any adjuvant treatment except for 
endocrine treatment is reported (Kiderlen et al. 2017). Chemotherapy in elderly breast 
cancer patients is used only after thorough patient evaluation and general treatment 
guidelines cannot be utilised on older, fragile patients. The role of the 
multidisciplinary team and physician is emphasised in clinical decision-making.   
Primary endocrine treatment   
Primary endocrine therapy is an alternative to surgical treatment in elderly patients 
with ER-positive cancer. The use of primary endocrine treatment has increased 
significantly over the past decade, leading to the omission of surgery for elderly 
patients with resectable breast cancer (Hamaker et al. 2013). Primary endocrine 
treatment has been proven to result in inferior local disease control compared to 
primary surgery (Hind et al. 2006, Syed et al. 2011, Hughes et al. 2013). Moreover, 
endocrine treatment also has side effects: fatigue, dizziness, nausea, muscle weakness 
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and pain as well as increased risk in thromboembolic complications. Advanced age, 
comorbidities and frailty—all reasons to consider non-surgical treatment—affect the 
patients’ ability to tolerate endocrine treatment and may lead to a poor QoL and 
decreased compliance. These long-term negative effects should be taken into account 




6 Aims of the study   
1. The quality of preoperative diagnostics and hospital volume influence the   
quality of the surgical treatment process and waiting times in breast cancer patients  
 
2. Day surgery is feasible in breast cancer surgery  
 
3. Oncoplasty improves aesthetic outcomes compared to conventional breast 
resection   
 
4. Surgical treatment in elderly breast cancer patients is well tolerated and 
improves oncological outcomes 
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7 Patients and methods 
 
This work was conducted at the Breast Surgery Unit, Comprehensive Cancer Center 
of the Helsinki University Hospital. Study I included 1307 patients undergoing 
primary breast cancer surgery during 2010 in the Helsinki and Uusimaa Hospital 
District. Patients with recurrent breast cancer, other malignant tumours in the breast 
or secondary surgeries were excluded. If bilateral breast cancer was detected, the 
tumour in a more advanced stage was used as the index tumour.   
Study II was a randomised controlled trial and included 78 patients receiving BCS 
and SNB between January 2008 and March 2011. Patients were randomised in two 
groups: day surgery discharge and overnight stay. Results were analysed according to 
randomisation and actual treatment.    
In study III, 637 patients receiving breast-conserving treatment due to unilateral 
primary breast cancer in 2010 were included. These patients received a questionnaire 
regarding aesthetic and functional outcomes: 379 patients answered the questionnaire 
and were included in the analysis. Patients with mastectomy as reoperation due to 
insufficient free tissue margin were excluded.   
Study IV included 446 patients older than 80 years with primary early breast cancer 
between January 2005 and December 2010. The follow-up period ended on December 
31st, 2014, and patients’ survival status (alive, breast cancer–related death, death for 
other cause) as of that date was obtained from the Finnish Cancer Registry. Data on 
cancer recurrences were collected from hospital records. The follow-up period was 
calculated from the day of surgery until the end of the follow-up period or death.   
The study protocol was approved by the Ethics Committee of the Department of 
Surgery, Helsinki University Central Hospital. 
7.1 Surgery 
 
Breast and axillary surgery were performed or supervised by expert breast 
surgeons. In patients with breast conservation, a conventional wide local excision was 
performed, aiming at 1 cm free lateral margins and usually including the underlying 
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pectoral fascia and a slice of skin overlying the tumour. After resection, adequate 
mobilisation and closure of breast parenchyma were performed. Oncoplastic resection 
refers to first- and second-level oncoplastic procedures (Clough et al. 2010). In Study 
III, the following oncoplastic resection techniques were used: racket mammoplasty, 
reduction mammoplasty techniques, round block, rotationplasty techniques, extensive 
dual plane undermining and other oncoplastic techniques.  
SNB was performed on patients with invasive breast cancer who had clinically 
node-negative breast cancer. The indications and contraindications for SNB according 
to the tumour size varied during the study period. In patients with DCIS, SNB was 
performed when mastectomy was performed. Also, if invasive cancer was suspected 
in breast imaging or core needle biopsy, SNB was recommended. ALND was omitted 
whenever the SNB was negative. SNB was performed using preoperative 
lymphoscintigraphy, intraoperative identification of the sentinel nodes with gamma 
probe and blue dye.  
ALND was performed in node-positive patients, either after positive SNB or after 
axillary ultrasound with a tumour-positive needle biopsy of a suspicious node. ALND 
included the evacuation of Berg levels I and II nodes. Berg level III was palpated and 
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Table 1. Patient and tumour characteristics 
Study I: 1307 patients with surgery for primary breast cancer 
Study II: 78 patients with breast-conserving surgery and SNB 
Study III: 379 breast cancer patients with breast-conserving surgery 
Study IV: 446 patients older than 80 years with primary breast cancer 
  
       Study I Study II    Study III Study IV 
Age, median (range) years 62 (22–100) 56 (40–69)  84.5 (80.0–
101.9) 
Histological T-stage Tis & T1mi 97 (7%)  23 (6.1%) 15 (3.4%) 
T1 813 (62%)  302 (79.7%) 207(46.4%) 
T2 306 (23%)  51 (13.5%) 194 (43.4%) 
T3-4 71 (5%)  0 26 (5.8%) 
NA 20 (2%)  3 (0.8%) 4 (0.9%) 
Axillary lymph node 
status 
N0 774 (59%) 62 (79.5%) 270 (71.2%) 187 (42%) 
N1mi 82 (6%)   7 (2%) 
N1 237 (18%) 16 (20.5%) 91 (24.0%) 94 (21%) 
N2-3 156 (12%)   66 (15%) 
NA 58 (4%)  18 (4.7%) 92 (21%) 
Histological grade 1 306 (24%) 24 (30.8%) 111 (29.3%) 84 (21%) 
2 537 (42%) 36 (46.2%) 165 (43.5%) 155 (39%) 
3 433 (34%) 17 (21.8%) 100 (26.4%) 160 (40%) 
NA 31 (2.4%) 2 (2.6%) 2 (0.5%) 47 (10.5%) 
Tumour ER content positive 1025 (85%) 68 (87.2%)  370 (88%) 
negative  3 (3.8%)  50 (11%) 
NA  7 (9.0%)  26 (5.8%) 
Tumour PR content positive 797 (66%) 60 (77.0%)  268 (65%) 
negative  11 (14.1%)  146 (33%) 
NA  7 (9.0%)  31 (7.0%) 
HER2 amplification positive 158 (13%) 21 (27.0%)  39 (9%) 
negative  41 (52.6%)  341 (76%) 
NA  11 (14.1%)  66 (15%) 
Tumour multifocality positive   17 (4.4%)  
Histological type DCIS 96 (7%) 4 (5.1%) 24 (6.3%) 15 (4%) 
Ductal 871 (68%) 68 (87.2%) 298 (78.6%) 294 (69%) 
Lobular 185 (14%) 6 (7.7%) 39 (10.3%) 67 (16%) 






The breast surgery specimens were oriented by the surgeon and were sent unfixed to 
the specialised breast pathologist for assessment. The primary tumour diameter, 
presence of multifocality, histological tumour type and grade, ER and PR status, MIB-
1 proliferation index and HER2 amplification status were analysed as described in 
Leidenius et al. (2010). 
Sentinel nodes were sent to the pathology laboratory separately from the primary 
tumour for frozen section analysis. Tumour deposits were classified as 
micrometastases at ≤2 mm in diameter and as ITCs at ≤0.2 mm in diameter. The 
longest diameter of the largest metastasis was recorded as the size of metastasis. The 
assessment of sentinel nodes and the nodes from the axillary lymph node dissection 
specimen is described in detail in a previous study (Meretoja et al. 2010).  
7.3 Adjuvant treatment 
 
Systemic adjuvant treatment and RT were individually planned by the 
multidisciplinary breast cancer team based on patient and disease characteristics 
according to national guidelines. RT to the ipsilateral breast was given after breast-
conserving surgery using a linear accelerator to a cumulative dose of 50 Gy in 25 
fractions. A booster dose of 10–16 Gy given in five to eight fractions was given to 
premenopausal women as well as in patients with close resection margins. The whole 
breast was treated from two tangential fields. Post-mastectomy RT was given to 
patients with a large primary tumour (pT3 or pT4) and to patients with axillary lymph 
node–positive cancer. RT was based on computer-based dose planning and was given 
in a linear accelerator with 2 Gy daily fractions, five fractions per week for a 
cumulative dose of 50 Gy.   
For systemic adjuvant treatment, an estimated recurrence rate of over 10% across 
ten years was considered a threshold value. In addition to cancer-related factors, 
patient comorbidities, general condition and age were also taken into account when 
evaluating the advantages and disadvantages of systemic adjuvant treatment. Patients 
with HER2-positive breast cancer received trastuzumab concomitantly with 
chemotherapy if no clinical contraindications existed. Hormone therapy was initiated 
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after chemotherapy or simultaneously with RT if chemotherapy was not planned.  
Premenopausal women with ER- and/or PR-positive cancer received tamoxifen, and 
postmenopausal women received either tamoxifen or an aromatase inhibitor for five 
years. Only a few study patients received neoadjuvant treatment. 
7.4 Anaesthesia and day surgery 
Study II was a randomised controlled trial. All patients were eligible for day surgery 
in the preoperative assessment. Patients who were randomised to the day surgery 
group were discharged on operation day if day surgery criteria were met and their 
condition allowed it. Criteria for day surgery discharge on the operation day were as 
follows: BCS and SNB without drainage, stable blood pressure and pulse level, no 
respiratory problems, patient mobilised to the preoperative level, no or only mild 
nausea, postoperative pain controlled by oral pain medication, either non-steroidal 
anti-inflammatory analgesic, paracetamol or paracetamol-codeine, no or minimal 
postoperative bleeding, normal urination, adult companion at home and patient being 
first on the operation schedule. 
In study II, general anaesthesia was induced with propofol and fentanyl and 
maintained with propofol and remifentanil infusions. All patients were intubated and 
received rocuronium for muscle relaxation. Dexamethasone and granisetron were 
given for prophylaxis of postoperative nausea and vomiting. To manage pain at home, 
ibuprofen and paracetamol or paracetamol with codeine were prescribed. 
7.5 Quality indicators 
There are no validated and tested quality indicators for breast cancer patients in 
Finland. In Study I, the following parameters were modified from the EUSOMA 
recommendations (Del Turco et al. 2010) and used as quality indicators:  
- proportion of patients having BCS 
- proportion of mastectomy patients receiving IBR 
- proportion of oncoplastic resections of all BCS 
- need for re-operation due to insufficient resection margins 
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- need for re-operation due to false-negative sentinel nodes in the intraoperative 
assessment 
- failure in identifying sentinel node 
- ALND in node negative patients 
- time from referral to surgery 
- time from surgery to adjuvant therapy 
- number of cancer operations.  
 
Municipal authorities organize breast cancer screening in Finland. Biannual 
screening is offered to all women aged 50–69. According to the Health and Social 
Services Ministry statistics, screening participation in 2010 was 85% nationally and 
79% in the Helsinki and Uusimaa Hospital District. Patients are referred to breast 
surgery units either from population-based screening or by other public or private 
healthcare providers. Before referral to the hospital for breast cancer surgery, 
diagnostic mammogram and ultrasound together with percutaneous needle biopsy of 
the primary tumour are required. 
7.6 Hospital volume and facilities 
In Finland, the treatment of malignant diseases is almost exclusively performed by the 
public health care system. Regional healthcare districts organise the treatment. The 
number of breast cancer operations in each hospital is mainly dependent on the size of 
the population and incidence of breast cancer within its well-defined area. Some 
special cases, such as those with IBR, are referred to high-volume hospitals.  
The Helsinki and Uusimaa Hospital District is the largest hospital district in 
Finland based on a population of more than 1.6 million people (2017). In 2010, breast 
cancer surgery was performed in five hospitals receiving patients mainly from their 
own defined areas. In Study I, hospitals A and B were high-volume (>150 patients 
annually), hospital C was medium-volume (100–150 patients), hospital D low-volume 
(50–99 patients) and hospital E very low-volume (<50 patients). Hospitals A and B 
are located in big cities, whereas hospitals C, D and E are located in smaller towns, 
surrounded by more rural-like areas. Nuclear medicine as well as MRI facilities are 
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located in Hospitals A and B. All hospitals performed SNB using similar surgical 
principles and histopathological methods.  
Systemic adjuvant treatment and RT were individually planned by the 
multidisciplinary breast cancer team based on patient and disease characteristics 
according to national guidelines. All study patients receiving adjuvant or neoadjuvant 
therapies were referred to a single institute, the Department of Oncology at Helsinki 
University Hospital. 
7.7 Questionnaires 
In study II, the patients and their spouses or other relatives received study 
questionnaires. These questionnaires evaluated their perceptions of day surgery and 
physical and psychological recovery within discharge.  The questionnaires were not 
validated. They were filled out on the first postoperative day and returned by mail. 
Questionnaire results were analysed for patients receiving BCS and SNB only. 
Altogether, 44 (72%) patients returned the questionnaires, including 20 patients 
randomised to the day surgery group and 24 to the overnight stay group. Results were 
analysed according to randomisation and actual treatment received, that is, per 
protocol. When analysed according to actual treatment, 18 patients received day 
surgical treatment and 26 received an overnight stay. 
In Study III, aesthetic and functional outcomes were evaluated with the use of two 
separate questionnaires: BCTOS and an author-created questionnaire (Appendix 1). 
Questionnaires and informed consent forms were sent three years after surgery by 
mail, with a prepaid return envelope included. Altogether, 379 (59%) patients agreed 
to take part in the study by returning questionnaires and signed informed consent 
forms. Of these, 293 (77%) had conventional BCS and 86 (23%) oncoplastic BCS. 
The proportion of conventional and oncoplastic procedures in the whole study 
population was similar at 79% and 21%, respectively. 
BCTOS was designed to assess the woman’s subjective evaluation of the aesthetic 
and functional outcomes after breast cancer treatment (Stanton et al. 2001). The 
BCTOS questionnaire addresses many important dimensions of post-treatment 
morbidity with respect to aesthetic and functional outcomes, specifically targeting the 
surgical aspects of BCS. We translated the BCTOS questionnaire into Finnish and 
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Swedish since, to our knowledge, it has not been used in Finland before. Patients rate 
different items according to symmetry between the treated and the untreated breast on 
a four-point scale (1 being no difference between the treated and untreated breast, and 
4 being a large difference between the treated and untreated breast). BCTOS consists 
of three internally consistent scales, which are defined as Aesthetic, Functional and 
Sensitivity status. The score value of each subscale is the mean of items belonging to 
this scale. We defined the BCTOS aesthetic status cutoff value of ≥3 to be a poor 
aesthetic outcome. A BCTOS aesthetic score of 2.0–2.99 was considered intermediate, 
and <2 was considered a good aesthetic outcome.    
Another author-created questionnaire focused on the aesthetic outcome of the 
operated breast. In this five-point questionnaire, patients were asked about their 
opinion of  the aesthetic outcome of the operated breast in general and in some specific 
areas, such as breast size, nipple appearance and position, breast shape and position, 
scar tissue, fitting of bra and symmetry to contralateral breast. The questionnaire also 
asked if patients had any problems in everyday life due to the poor aesthetic outcome. 
7.8 Statistical analyses 
The medians of continuous variables were compared using the Mann-Whitney U and 
Kruskal-Wallis tests. Categorical variables were compared using the Chi-squared test.  
In Study II, four graded questionnaire answers were categorised into binomial 
variables for statistical analyses so that alternatives 1 and 2 were combined as well as 
alternatives 3 and 4. In the BCTOS questionnaire (Study III) to compare individual 
items between conventional and aesthetic groups, a four-point scale was categorised 
into two groups for statistical analyses, so that alternatives 1 and 2 (good or excellent 
outcome) were combined as well as alternatives 3 and 4 (intermediate or poor 
outcome). 
Distant disease-free survival (DDFS) was calculated from the date of diagnosis to 
the date of the first occurrence of breast cancer metastases outside the regional lymph 
nodes. BCSS was calculated from the date of diagnosis to the date of death due to 
breast cancer and OS from the date of diagnosis to the date of death from any cause.  
Patients alive without cancer recurrence were censored on the completion date of the 
follow-up period. Life tables were constructed according to the Kaplan-Meier method, 
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and survival between groups was compared with the log-rank test. P-values of <0.05 




8.1 Quality of preoperative diagnostics and surgery and 
their impacts on delays in breast cancer treatment 
(Study I)   
Patient and tumour characteristics 
More than half of the patients (n=774, 59%) were node-negative with a significant 
difference between hospitals (p= 0.005). In hospital E, patients were eldest (median 
66, range 44–89 years old), the proportion of T3-T4 tumours was significantly higher 
(20%; p<0.001) and these patients more often had grade 3 tumours (47%; p=0.029) 
(Table 8.1). 
Patient referral and preoperative examination 
The need for additional diagnostic imaging and biopsies was significantly different 
between hospitals, ranging from 33% in hospital D to 3% in hospital E (p<0.001).  The 
need for additional diagnostic procedures was significantly different according to the 
referring institute (p<0.001) in both additional conventional diagnostic procedures and 





















Table 8.1. Study population and tumour charactristics 
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26 (20%) 16 (28%) 7 (20%) 
T3-T4 71 (5%) 25 (4%) 20 (5%) 16 (13%) 3 (5%) 7 (20%) 
N.A. 20 (2%) 12 (2%) 5 (1%) 1 (1%) 2 (4%) 0 






80 (64%) 33 (57%) 17 (50%) 0.005 





86 (22%) 21 (17%) 4 (7%) 8 (23%) 
N2, N3 156 
(12%) 
77 (11%) 44 (11%) 19 (15%) 10 (18%) 6 (18%) 





















42 (34%) 16 (30%) 16 (47%) 






92 (79%) 41 (77%) 28 (85%) 0.070 






80 (68%) 33 (62%) 23 (70%) 0.800 
HER2 positive 158 
(13%) 
74 (12%) 47 (13%) 20 (17%) 10 (19%) 7 (21%) 0.173 
Histological 
type 







84 (68%) 43 (75%) 23 (69%) 
Lobular 185 
(14%) 





92 (13%) 13 (6%) 21 (17%) 4 (7%) 4 (12%) 
Adjuvant 
treatment 






























13 (1%) 9 (1%) 2 (1%) 0 2 (3%) 0 





Table 8.2. Patient referral and need for additional hospital diagnostics 
 
 













































None 1054  
(81%) 







80 (11%) 36 (9%) 8 (6%) 14 (25%) 1 (3%)   
MRI 114 (8%) 65 (9%) 44 (11%) 0 5 (8%) 0   
Surgical 
biopsy 
  23 (2%)  8 (1%) 10 (2%) 3 (2%) 1 (1%) 0 0.743 
 
Surgery 
In 664 (51%) patients, the final breast surgery was BCS, with no difference between 
hospitals (p=0.781). Of the 664 patients with BCS as the final surgery, 522 (79%) 
received conventional resection and 142 (21%) oncoplastic resection. The rate of 
oncoplastic resection varied significantly between hospitals: hospital A was clearly 
performing more oncoplastic surgery than others (p<0.001). Between two high-
volume centres (A and B), there was a significant difference in IBR rate (p=0.004, 
Table 8.3).   
Altogether, 1259 (96%) patients underwent axillary surgery. Of these, 655 (50%) 
received SNB only and 362 (28%) received ALND after SNB. SNB was unsuccessful 
in 12 (1%) cases and 9 (75%) of these patients received ALND. Fifty-one node-
negative patients underwent ALND, comprising of 7% of all node-negative patients. 
There was a significant difference between hospitals (p=0.009, Table 8.3). Of these 
51 patients, 6 with upfront ALND received neoadjuvant treatment and were node-
negative in postoperative pathological assessment. Nineteen patients with positive 
sentinel nodes (5% of all patients with positive SNB) had no ALND. Most often, these 
patients had isolated tumour cells (ITC) 14 (74%) or micrometastases 3 (16%). In 38 
(10% of all ALND after SNB) cases, ALND was performed as a second operation due 
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to a false negative result in the intraoperative assessment of sentinel nodes with a 
significant difference between hospitals (p<0.001, Table 8.3). 
Complications demanding surgical intervention were rare: 1243 (95%) patients 
had none. Postoperative haematoma was the most common complication: 45 (3%) 
patients underwent haematoma evacuation. 
Altogether, 1143 (88%) patients had only one cancer operation. Additional cancer 
operations were performed in 160 (12%) patients, of whom 151 (11%) received two 
operations and 9 (1%) received three operations. Reoperation due to an insufficient 
tumour-free tissue margin was performed in less than 8% (N=99) of patients. The 
reoperation was a mastectomy in 77 (78%) patients, 28 (28%) of which had IBR.   
After secondary mastectomy IBR occurs more often than with primary mastectomy 
(46 patients, 9%; p<0.001). 
Waiting time 
Waiting times from referral to primary surgery and from primary surgery to initiation 
of any adjuvant treatment are shown in Table 8.4. The waiting time for radiation 
therapy is shown for patients who did not receive chemotherapy. In this group, 
endocrine therapy may have been started before RT. Patients receiving neoadjuvant 
treatment (n=13) were excluded from the waiting time analysis. 
The median waiting time from referral to primary surgery was 24 days (range of 
1–188) (Table 8.4a). Additional biopsies, preoperative MRI and IBR increased the 
median wait time significantly (Table 8.4b). Altogether, 1166 (89%) patients received 
adjuvant treatments. The median waiting time from primary operation to initiation of 
any adjuvant treatment was 47 days (range of 8–112), and it differed significantly 
between hospitals (p=0.005, Table 8.4a). Wait times for the initiation of adjuvant 
treatment were significantly affected by type of primary surgery and number of cancer 
operations (Table 8.4c). In eight patients, the delayed adjuvant treatment was due to 














































































(20%) 1 (1%) 0 0 <0.001 
Final axillary surgery <0.001 












































38 (3%) 20 (3%) 8 (2%) 1 (1%) 8 (14%) 1 (3%) 
SNB unsuccessful 0.698 
 12 (1%) 7 (1%) 2 (1%) 3 (3%) 0 0  
ALND of N0 axilla 0.009 
 51 (7%) 19 (5%) 16 (8%) 8 (10%) 4 (14%) 4 (27%)  
Positive SNB, no ALND  
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Table 8.4b. Waiting times for surgery 
 
  




yes  (N=90) 37 (22-153) 
<0.001 
no (N= 1217) 23 (1-188) 
Preoperative MRI 
yes (N=114) 34 (22-146) 
<0.001 
no (N= 1193) 23 (1-188) 








mastectomy (N=639) 25 (4-188) 
0.002 




Table 8.4c. Waiting times for adjuvant treatment 
 
 Wait time from primary surgery to adjuvant treatment, days p-value 






mastectomy IBR 0.011* 
47 (8–112) 48 (19–90) 46 (11–95) 54 (30–
83) 
Number of cancer 
operations, 
median (range)** 
1 2 3  <0.001 
49 (5–120) 57 (26–125) 85 (56–90) 
*between mastectomy and IBR 
** Only patients receiving chemotherapy and/or radiation 
 
8.2 Feasibility of day surgery after breast-conserving 
surgery and SNB (Study II) 
Hospital discharge 
In the day surgery group, 18 (47%) patients were discharged the same day, whereas 
20 (53%) stayed at least one night in hospital (Figure 8.1). The most common reason 
for overnight hospital stay was ALND (9 patients). Other reasons included drainage 
(one patient), patient’s wish for overnight stay after surgery (one patient) and not being 
first on the operation schedule (one patient). Day surgery discharge criteria were not 
met in six patients. Reasons for an overnight stay were missing for two patients. 
Altogether, 60 patients stayed one night or longer in hospital; 40 patients were 














Figure 8.1. Patient randomisation and actual treatment groups 
 
 
Perception of day surgery 
There were no statistically significant differences in physical and psychological 
symptoms between day surgical discharge and overnight stay groups regardless of 
whether they were analysed according to randomisation or actual treatment. For 
individual symptoms, see Tables 8.5 and 8.6.   
All patients randomised to day surgery and treated accordingly would choose day 
surgery again. Similarly, their spouses’ or relatives’ perceptions of day surgery were 
positive. For both randomised and actual treatment groups, the majority of patients 
randomised to overnight stay (67%) or who had stayed overnight regardless of 
randomisation (61%) would not choose day surgery over overnight stay in the future 
(p<0.0001).  
Patients in both groups had rather similar experiences regarding the first 
postoperative day and their psychological well-being. Also, spouses’ or relatives’ 




Table 8.5. Questionnaire results, actual treatment groups and percentages of answers  
 
 Day Surgery 
N=18 
















tired 13(72%) 5 (28%) 14 (54%) 12(46%) 0.218 
anxious 18 (100%) 0 22 (88%) 3 (12%) 0.128 
nervous 18 (100%) 0 23 (96%) 1 (4%) 0.381 
irritated 18 (100%) 0 24 (100%) 0  
depressed 18 (100%) 0 24 (96%) 1 (4%) 0.391 
insecure 18 (100%) 0 23 (92%) 2 (8%) 0.219 
desperate 18 (100%) 0 25 (96%) 1 (4%) 0.400 
lonely 18 (100%) 0 25 (100%) 0  
weak 13 (100%) 0 13 (93%) 1 (7%) 0.326 
short of breath 18 (100%) 0 25 (100%) 0  
pain 18 (100%) 0 22 (88%) 3 (12%) 0.128 
sleepless 16 (89%) 2 (11%) 21 (81%) 5 (19%) 0.469 
appetite loss 13 (87%) 2 (13%) 15 (100%) 0 0.143 
nausea 18 (100%) 0 23 (92%) 2 (8%) 0.219 
headache 18 (100%) 0 23 (92%) 4 (8%) 0.219 
need for emotional support 18 (100%) 0 26 (100%)   
Spouse feels:      
tired 14 (82%) 3 (18%) 21 (88%) 3 (12%) 0.646 
anxious 14 (82%) 3 (18%) 21 (88%) 3 (12%) 0.212 
nervous 17 (100%) 0 21 (91%) 2 (9%) 0.394 
irritated 17 (100%) 0 23 (96%) 1 (4%) 0.802 
depressed 16 (94%) 1 (6%) 23 (96%) 1 (4%) 0.394 
insecure 17 (100%) 0 23 (96%) 1 (4%) 0.394 
sleepless 17 (100%) 0 23 (96%) 1 (4%) 0.482 
lonely 16 (94%) 1 (6%) 21 (88%) 3 (12%)  
desperate 17 (100%) 0 24 (100%) 0 0.588 
able to support patient 3 (19%) 13 (81%) 3 (12%) 21 (88%) 0.767 
able to discuss with patient 1 (6%) 16 (94%) 2 (8%) 22 (92%) 0.767 
need for more conversation 










Table 8.6. Questionnaire results, actual treatment groups and percentages of answers 
 
 
8.3 Aesthetic and functional outcomes after breast-
conserving surgery (study III) 
Tumour and patient characteristics in conventional resection and 
oncoplastic resection groups 
Patients in the oncoplastic resection group had significantly larger median tumour 
diameters (16.0 mm vs. 12.0 mm; p<0.001), and they had multifocal tumours more 
often (12% vs. 5%; p=0.032) and therefore also larger resection specimens (97 g vs. 
61g; p<0.001) and node-positive cancer (30% vs. 22%; p=0.029). They also had lower 
quadrant tumour localisation more often (25% vs. 19%; p=0.007). ALND was 
performed significantly more often in the oncoplastic resection group (p=0.007), 
reflecting the difference in nodal status between groups. There was no statistical 
difference between groups in receiving radiation therapy and tumour bed boosters. 
Surgery 
Oncoplastic resection techniques were used as follows: 19 (22%) racket 
mammoplasties, 19 (22%) reduction mammoplasty techniques, 16 (19%) round block, 
16 (19%) rotationplasty techniques, 12 (14%) extensive dual plane undermining and 
 Day surgery N=18 Overnight stay N=26  
 Yes No Yes No P-value 
Patient feels able to talk about 
cancer and her feelings during 
the first 24h after surgery 
18(100%) 0 25(96%) 1(4%) 0.400 
Patient feels that she has 
received enough support 
18(100%) 0 24(92%) 2(8%) 0.228 
Patient feels that she has 
received enough information 
17(94%) 1 (6%) 25(96%) 1(4%) 0.789 
Patient would choose day 
surgery in the future 
18(100%) 0 10(39%) 16(61%) 0.000 
Patient had to contact hospital 
after discharge 
2(11%) 16(89%) 1(12%) 7(88%) 0.919 
Spouse considers the length of 
hospital stay appropriate  
17(100%) 0 23(96%) 1(4%) 0.000 
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4 (5%) other oncoplastic techniques. A contralateral breast symmetry procedure was 
performed in 20 (23%) patients in the oncoplastic group compared to 3 (1%) in the 
conventional resection group (p<0.001). The re-resection rate due to tumour-positive 
margins was low in both groups: 12 patients (4%) in the conventional resection group 
and 3 patients (3%) in the oncoplastic group received a second resection. Due to the 
study plan, patients receiving mastectomy as a second operation were excluded. There 
was no difference in surgical complications requiring a reoperation, which were 5 
(2%) in the conventional group and 3 (3%) in the oncoplastic group (p=0.309).  
Axillary surgery, either SNB or ALND, was performed in 364 (96%) patients.  
Axillary surgery in the oncoplastic group was more extensive than in the conventional 
resection group: 35 (41%) received ALND in the oncoplastic group compared to 77 
(26%) in the conventional resection group (p=0.007). 
Aesthetic outcome 
Aesthetic outcomes according to the BCTOS questionnaire were good in 284 
(75%) patients. Good aesthetic outcomes were reported by 52 (61%) patients in the 
oncoplastic group and 230 patients (81%) in the conventional resection group 
(p<0.001). The mean BCTOS aesthetic score was worse after oncoplastic resection 
than after conventional resection (mean 1.84 vs. 1.62; p=0.002).  Oncoplastic resection 
appears to be worse in almost every BCTOS aesthetic category (Table 8.7).   
According to the author-created questionnaire, 217 patients (75%) in the 
conventional resection group and 61 patients (72%) in the oncoplastic resection group 
reported good or excellent aesthetic outcomes (p=0.441). However, nipple position 
and appearance were significantly better in the conventional resection group; 112 
(39%) patients reported excellent outcomes compared to 24 (29%) in the oncoplastic 
group (p=0.019). The breast scar was also evaluated significantly better in the 
conventional resection group; excellent results were reported in 115 (40%) patients 
compared to 23 (27%) patients in the oncoplastic group (p=0.040). For breast size, 
position and shape, there were no significant differences between groups.  





Table 8.7. BCTOS aesthetic subscale. Individual item comparison between groups 
 







Breast size 245 (86%) 60 (72%) 0.003 
Breast texture 256 (90%) 65 (79%) 0.011 
Nipple appearance 246 (88%) 59 (75%) 0.005 
Breast shape 251 (88%) 63 (76%) 0.006 
Breast position  260 (92%) 64 (77%) <0.001 
Breast Scar 237 (83%) 59 (72%) 0.024 
Fit of clothing 266 (94%) 78 (93%) 0.706 
  
Factors influencing aesthetic outcomes 
Patient and tumour characteristics were analysed more closely to examine reasons for 
poor aesthetic outcomes. Larger tumour diameter (p=0.033), tumour multifocality 
(p=0.022), weight of the resection specimen (p<0.001) and oncoplastic surgery 
(p<0.001) were predicting poor aesthetic outcomes in the BCTOS aesthetic subscale 
when all patients were included in the analyses. Aesthetic outcomes were not affected 
by tumour localisation (p=0.829). Neither RT (p=0.261) nor tumour bed boosters 
(p=0.231) affected the BCTOS aesthetic outcome. 
BCTOS aesthetic outcome results were analysed separately in the conventional 
and oncoplastic resection groups. Tumour multifocality (p=0.013) remained a 
predictor of poor aesthetic outcomes in the conventional resection group but was not 
predictive in the oncoplastic resection group (p-value 0.836 for multifocality). Tumour 
localisation had no statistically significant effect on aesthetic outcomes. In the 
oncoplastic resection group, there was a significant difference in aesthetic outcomes 
between techniques (p=0.025): extensive dual plane undermining provided poor 
aesthetic outcomes more often than others. Reduction mammoplasty and round block 
techniques provided good aesthetic outcomes most often. 
The re-resection rate, surgical complication rate and contralateral breast symmetry 




Breast resection did not significantly affect functional status three years after surgery 
in the BCTOS questionnaire (BCTOS mean 1.345 in the conventional and 1.357 in 
the oncoplastic resection group; p=0.866). Results were also analysed according to 
axillary procedure. As expected, the functional status was worse after ALND when 
compared with SNB only (BCTOS mean 1.255 after SNB and 1.547 after ALND; 
p<0.001). In further analyses, we did not find other factors affecting functional status 
except the nodal stage, which determined the extent of axillary surgery. 
 
8.4 Surgical treatment and prognosis in elderly patients 
of 80 years and older with breast cancer (Study IV)  
The median age of all patients was 84.5 years (range 80.0–101.9 years). The median 
age of patients receiving surgery was 84.1 years (range 80.0–101.9 years) and of those 
not receiving surgery, it was 86.5 years (range 82.2–90.8 years; p=0.347). Altogether, 
384 (86.1%) patients had one or more comorbidities: 254 (57.0%) had hypertension, 
120 (27.0%) had ischaemic cardiac disease, 147 (33.0%) had another severe 
cardiovascular disease (i.e., atrial fibrillation, atherosclerosis), 65 (14.6%) had 
diabetes, 57 (12.8%) had dementia, 42 (9.4%) had pulmonary disease and 123 (37.0%) 
had some other severe disease such as rheumatoid arthritis, kidney failure or 
psychiatric disease. In 94 (21.1%) cases, the general condition of the patient 
influenced the treatment. Patient preference influenced the treatment in 43 (9.6%) 
cases.   
Patients with surgery 
Surgery on the primary tumour was performed in 401 patients (90.0%). Surgery was 
performed under local anaesthesia in 12 patients (3%). Axillary surgery was 
performed in 352 (78.1%) patients. Altogether, 32 (26.2%) patients undergoing 
upfront ALND were axillary node–negative. In 69 (15.4%) patients, the general 
condition affected surgical treatment: surgery was either omitted or was less extensive. 
Recommended surgery was completely omitted in nine cases due to the patient’s 
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preference. Altogether, 15 (3.7%) patients received mastectomy in order to avoid 
radiotherapy.  
Adjuvant treatment was given to 302 (75.3%) patients. RT was received by 66 
(56.4%) patients after BCS and 68 (23.9%) patients after mastectomy. Endocrine 
therapy was received by 259 (85.8%) patients. None of the patients received 
chemotherapy. In 27 (6.7%) cases, the general condition of the patient influenced the 
adjuvant treatment recommended by the medical oncologist. The patient’s preference 
changed the recommended adjuvant treatment in 37 (9.2%) cases: 30 patients refused 
RT and 7 refused hormonal treatment.   
Patients without surgery 
Surgery was not performed in 45 (10.1%) patients; it was omitted due to poor general 
condition in 31 (69%) of these patients. Nine (20%) patients refused surgery. In five 
(11%) patients’ records, the reason for surgery omission was not clearly stated. 
Regarding comorbidities, patients without surgery had ischaemic heart disease (20 
[44.4%] vs. 101 [25.2%]; p=0.006) and dementia (11 [24.4%] vs. 46 [11.4%]; 
p=0.013) significantly more often when compared to patients with surgery. There were 
no statistically significant differences between surgical and non-surgical treatment 
groups in the other recorded comorbidities. Endocrine therapy was given to 33 
(73.3%) of the patients without surgery. None of the patients received RT or 
chemotherapy. Twelve (26.7%) did not receive any oncological treatment. Reasons 
for omitting treatment were very poor general condition in nine cases and patients’ 
preference in two cases. In one case, the reason for omitting treatment was not clear 
from the patient report. 
Survival  
For all patients, the median follow-up period was 52 months (range 0–117 
months). For surgically treated patients, the median follow-up was 54 months (range 
1–117 months) and for patients without surgery, it was 18 months (range 0–82 
months). Overall, 226 (56%) patients receiving surgery died during the follow-up 
period. Of these deaths, 61 (27%) were breast cancer–related. None of the operated 
patients died within 30 days of surgery.  
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In patients with surgery, 81 (20%) had either histopathological T3-4 or N2-3 
disease or both, and 41 (49%) had a postoperative CT scan. Nine patients had distant 
metastases diagnosed in their CT scans; four of the nine died of breast cancer 3–55 
months after diagnosis, three died of causes unrelated to breast cancer and two were 
alive at the end of the follow-up at 49 and 83 months.  
 Of the non-surgically treated patients, 42 (93%) died during follow-up, 12 of 
(29%) died from breast cancer (Figure 8.2).   
The OS was significantly better in patients who received surgical treatment than 
in patients who did not. Five-year OS was 50.6% in the surgical treatment group and 
15.2% in the non-surgical treatment group (p<0.001; Figure 8.3a). Similarly, the 
BCSS was significantly better in patients with surgery when compared to patients 
without surgery. Five-year BCSS was 82.0% in patients with surgery and 56.0% in 
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In the entire study population, local and regional recurrences were diagnosed in 16 
(3.6%) and 6 (1.3%) patients, respectively. The median time from diagnosis to local 
recurrence was 13 months (range 3–49 months) and to regional lymph node recurrence 
35 months (range 7–61 months). Distant metastases were reported in 80 (17.9%) 
patients. The median time from the primary diagnosis to distant metastases was 51 
months (range 0–117 months), including the nine patients with distant metastases 
diagnosed in the postoperative CT scan. The five-year DDFS was 80.4% in patients 
with surgery and 53.3% in patients without surgery (p<0.001; Figure 8.3c). The 

















Figure 8.3b. Breast cancer-specific survival, comparison between surgical and non-





Figure 8.3c. Distant disease-free survival, comparison between surgical and non-
surgical treatment groups. 
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  N=401 (%) N=45 (%) p (log rank) 
Follow-up 
(months) Median 54 18  
 Range 1–117 0–82  
Events Local recurrence 16 (4%) 0 0.298 
 Contralateral breast cancer 0 0  
 
Regional lymph node 
recurrence 5 (1%) 1 (2%) 0.218 
 Distant metastasis 67 (17%) 13 (29%) <0.001 
 Breast cancer death 61 (15%) 12 (27%) <0.001 








9.1 Factors affecting breast cancer treatment and 
delays in treatment 
Delays in surgical treatment 
The referring institute has an impact on the breast cancer treatment process: patients 
referred by private clinics had significantly more additional diagnostic procedures. 
This possibly reflects differences in patient characteristics but also in clinical practice 
and expertise. Our study results confirm earlier findings that additional diagnostics, 
including biopsies as well as MRI, caused a delay in surgical treatment (Hulvat et al. 
2010, Hukkinen et al. 2008.). The use of additional diagnostic procedures was not 
equivalent in hospitals treating breast cancer, with no plausible explanation from 
differences in population or tumour characteristics. We noted that variation in the use 
of additional diagnostic procedures between units places patients in unequal situations 
since the use of additional biopsies increases the waiting time until primary surgery.  
Hospital volume  
There are reports showing that the high surgical volume of a hospital is associated 
with better OS and a higher BCS rate (McDermott et al. 2013, Peltoniemi et al. 2011, 
Gooiker et al. 2010, Vrijens et al. 2012), whereas other studies indicate that the role 
of surgical volume is not substantial (Kuo et al. 2013, Siesling et al. 2014). In the 
present study, hospital volume had no effect on BCS rate. However, the overall BCS 
rate was surprisingly low at only 51%. Accordingly, the BCS rate has continuously 
increased since 2010, being approximately 70% in 2017. The positive impact of high-
volume and treatment centralisation was seen in advanced oncoplastic and 
reconstructive techniques; most (83%) oncoplastic resections were performed in the 
two hospitals with the largest volumes. Similarly, IBR was clearly performed more 
often in patients treated in larger volume units.  
Regardless of hospital volume, SNB appeared to be of high quality, with a 
proportion of unsuccessful SNB as low as about 1% and a rate of ALND of node-
negative axillae acceptable. However, in low-volume hospitals, the rate of ALND in 
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node-negative patients was significantly higher without complete explanation from 
the study population, thus exposing patients to excess morbidity. During the last 
decade, indications for SNB have been extending rapidly (Mansel et al. 2006, Giuliano 
et al. 2011, Lucci et al. 2007, Rao et al. 2013). High-volume academic centres may 
have extended the indications of SNB faster, resulting in a higher quality of care. The 
role of SNB in axillary staging instead of ALND is well established, and a recent 
Cochrane review strengthens the SNB’s status as the gold standard in axillary staging 
in clinically node-negative patients (Bromham et al. 2017).   
In Finland, no official national quality criteria for breast cancer treatment have 
been established. The comparison of different breast cancer units as well as different 
countries is not simple since case-mix and organisational factors differ. In addition to 
tumour and nodal status–related factors, for example the existence of a screening 
program, national health insurance and funding policies as well as cultural differences 
may greatly influence treatment decisions.    
Number of cancer operations  
A low number of cancer reoperations reflects optimal preoperative imaging, optimal 
preoperative diagnosis and the staging and surgical treatment itself. In our study, the 
re-excision rate due to insufficient resection margins was very low, less than 8%. It 
is clearly lower than in previous studies, reporting approximately 17–26% re-
excision rates (McCahill et al. 2012, Wilke et al. 2014, Lovrics et al. 2010). On the 
other hand, the mastectomy rate was high, which may partly explain the low 
reoperation rate. Notably, the secondary mastectomy rate was almost 80%, even 
though the oncological safety of multiple excisions has been demonstrated earlier 
(Coopey et al. 2011), and secondary mastectomy rates reported earlier are clearly 
lower (McCahill et al. 2012, Lovrics et al. 2010). Also, only 12% of primary 
mastectomy patients received IBR, which is markedly less than the 40% 
recommended by the EUSOMA. However, national treatment recommendations are 
different in different countries, and for example, the need for postmastectomy RT  
influences treatment decisions. The IBR rate has significantly increased worldwide 
since the study period (Hong et al. 2018, Albornoz et al. 2013). In our unit, the rate 
of IBR was 19% in 2017. On the other hand, many patients who previously were 
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optimal candidates for mastectomy and IBR are currently treated with BCS, thanks 
to the oncoplastic approach.  
Delays in adjuvant treatment 
Delays in the initiation of adjuvant treatments are associated with worse breast cancer 
outcomes in patients with grade III, HER2 positive and triple negative breast cancer 
(Gagliato et al. 2014, Richards et al. 1999), while no consensus exists on the optimal 
time interval between surgery and adjuvant treatment.  In previous retrospective 
analyses, four weeks of delay in postoperative RT  increases locoregional recurrences 
by 11% (Chen et al. 2008). Additionally, a four-week delay in adjuvant systemic 
therapies increases the risk of recurrence by 16% and mortality by 15% (Yu et al. 
2013). In agreement with earlier studies, our results indicate that multiple cancer 
operations as well as IBR are causing delays in the initiation of adjuvant treatment. 
However, in our study, IBR was often performed as a second operation after failed 
BCS, which inevitably causes a delay in the initiation of adjuvant treatment. Currently 
at our institution, the patient will receive adjuvant chemotherapy before a second 
surgery to avoid delaying the initiation of chemotherapy. In the present study, the role 
of surgical complications in delaying adjuvant treatments could not be clarified 
properly since our data includes only complications that required surgical treatment. 
9.2 Day surgery in breast cancer treatment 
Our study shows that patient satisfaction after BCS is equally good in day surgery 
patients as in patients with overnight stay. The patients felt that they received sufficient 
information about their disease as well as counselling and emotional support 
regardless of the hospital stay. Patient satisfaction with day surgery was high; all day 
surgery patients would choose day surgery again in the future. However, two-thirds of 
patients in the overnight stay group would have chosen the same treatment again. In 
fact, patients may prefer the procedure they have already experienced but may fear the 
unknown.     
The rate of day surgical discharge was surprisingly low. In earlier studies, the 
discharge rate from day surgery in breast cancer patients was higher, between 86% 
and 100% in selected study populations (Marchal et al. 2005, McManus et al. 1994, 
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Seltzer et al. 1995, Marrazzo et al. 2007, Dooley et al. 2002). In our study, the most 
common reasons for overnight stay were ALND, inability to fulfil day surgical 
discharge criteria and use of drainages. This study was started in 2008 when there was 
not much knowledge about day surgery in breast cancer patients. Currently, neither 
ALND nor drainage are contraindications to day surgery at our unit. Moreover, ALND 
is no longer routine in all sentinel node–positive patients. Furthermore, breast 
conservation is feasible more often due to the evolution of oncoplastic techniques.  
Therefore, day surgery is a feasible option in an increasing number of breast cancer 
patients. Despite increasing possibilities for day surgery, general day surgical criteria 
set limits for discharge. In urban areas, distance is rarely the problem in day surgical 
discharge. However, an adult companion may not always be available. 
9.3 Aesthetic outcomes after breast-conserving surgery 
Factors affecting aesthetic outcomes 
Our study results indicate that conventional wide local excision provides good 
aesthetic outcomes in correctly selected patients. Patient-evaluated aesthetic outcomes 
were good or excellent in the majority of patients. Contrary to previous studies (Santos 
et al. 2015, Foersterling et al. 2014, Rezai et al. 2015), the tumour location did not 
affect the aesthetic outcome,  even in the conventional resection group. Successful 
patient selection and surgical technique may partly explain our better aesthetic results 
after conventional resection. Moreover, our conventional wide local excision includes 
adequate mobilisation and closure of breast tissue and actually represents level 1 
oncoplastic surgery (Clough et al. 2010). A larger resection specimen weight appears 
to be a predictor of poor aesthetic outcomes in this study as well as in previous reports 
(Hennings et al. 2015), although opposite results have been reported (Rezai et al. 
2015). However, we have no data on the tumour-breast volume ratio, which might 
represent the extent of resection better than resection specimen weight alone. In our 
study, either re-excision, complication surgery or radiation boost have no effect on 
aesthetic outcomes, differing from previous studies (Heil et al. 2012, Immink et al. 
2012, Vrieling et al. 2000). Nevertheless, the number of patients receiving surgery 
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because of complication or re-excision was low in this population; thus, we consider 
these results unreliable and incomparable to earlier studies.   
Oncoplastic surgery 
Interestingly, on the BCTOS aesthetic subscale, nearly all individual items were worse 
after oncoplastic resection than after conventional resection. However, this finding is 
most likely due to selection bias. Oncoplastic resection allows the excision of larger 
or multifocal tumours to obtain the best possible aesthetic outcomes. Accordingly, the 
oncoplastic resection group patients had large or multifocal tumours more often, and 
they also received more extensive axillary surgery, as reported in earlier studies 
(Santos et al. 2015). Larger tumour diameter and tumour multifocality had a negative 
effect on aesthetic outcomes as expected and previously reported (Heil et al. 2012), 
although a statistically significant difference was not found when analysing the 
oncoplastic resection group alone.   
A more extensive remodeling of breast tissue, performed in oncoplastic surgery, 
possibly leads to a notable difference in breast firmness and shape. The main goal of 
oncoplastic BCS is to avoid deformity. Many oncoplastic techniques cause more 
visible and longer scars and include centralisation of the nipple-areola complex, which 
may affect the patient’s appraisal. With no deformity, the patient focus is on the scar 
and symmetry. Moreover, patients receiving oncoplastic resection have no knowledge 
about how poor the aesthetic outcome could be after conventional resection in their 
case.  
For the aforementioned reasons, candidates for oncoplastic resection need to be 
informed about longer scars and possible asymmetry of the breasts. The need for a 
symmetrising procedure of the healthy breast needs to be evaluated and discussed with 
the patient. Thorough information about the patient is crucial in setting realistic 
expectations. Even after excellent aesthetic results, the patient may be dissatisfied. On 
the other hand, many patients are happy with their aesthetic outcomes, even when 
evaluated as inferior by the surgeon.  
Our study results indicate that oncoplastic surgery should not be a value itself. 
Conventional resection provides good or even excellent aesthetic outcomes in 
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correctly selected patients. The surgical technique in breast conservation should be the 
simplest and likely to provide a good aesthetic outcome.   
Methods in the evaluation of aesthetic outcomes 
Although aesthetic outcome is an essential quality indicator and an important endpoint 
in breast cancer surgery, treatment outcome measurement and especially surgical 
issues after BCT are lacking in standardised evaluation methods. Wide variation exists 
in the methodology of previous studies evaluating aesthetic outcomes after BCT, 
making a comparison of results difficult (Heil et al. 2011, Santos et al. 2015, 
Foersterling et al. 2014). A systematic review by Chen et al. (2010) underlines the 
need for better evaluation tools. This need is recognised: the BCTOS questionnaire is 
further developed for better usability (Hennings et al. 2018) and the Breast-Q 
questionnaire has a new module (the Breast-Q: breast-conserving therapy) for women 
undergoing lumpectomy with and without radiation for the treatment of breast cancer. 
Patient self-evaluation is acknowledged as a valuable method since the subjective 
experience is central to the assessment of QoL (Heil et al. 2010, Stanton et al. 2001).     
   Objective outcome measures are another way of evaluating aesthetic outcomes after 
breast cancer surgery. Within trials, a panel evaluation of photographs of the breast(s) 
is commonly used to evaluate cosmetic outcomes. A panel evaluation is time-
consuming and performed without a standardised measurement technique. In recent 
years, digitalised assessment techniques have been introduced. An example of one 
such technique is the BCCT.core software (Cardoso et al. 2007). A recent publication 
shows a good correlation between panel evaluation and BCCT.core as well as between 
these and Breast-Q. Thus, any of these methods could possibly be used in trials to 
evaluate aesthetic outcomes and QoL (Lagendijk et al. 2017). 
The most appropriate time to evaluate aesthetic outcomes after BCT and RT is at 
least two years postoperatively, due to the long-term effects of irradiation (Vrieling et 
al. 2000, Haloua et al. 2013). Previous studies concerning aesthetic outcomes after 
BCT and oncoplastic surgery also differ greatly regarding the evaluation time-point of 
aesthetic outcomes, varying from the immediate postoperative time (Foersterling et al. 
2014, Heil et al. 2012) to several years after surgery (Immink et al. 2012). A study by 
Hennings et al. (2015) did not find a difference in aesthetic outcomes postoperatively 
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after BCT versus at the 1–2 year follow-up. Aesthetic outcomes are commonly 
evaluated one year after surgery when the breast is still oedematic after RT, especially 
in patients who have received adjuvant chemotherapy before RT. Fibrosis and scar 
retraction occur later, deteriorating aesthetic outcomes. We evaluated aesthetic 
outcomes three years after surgery, thus waiting a sufficient amount of time after 
radiation therapy has passed to visualise the effects of irradiation and the booster.   
9.4 Surgical treatment and survival in breast cancer 
patients over 80 years of age 
The management of elderly patients with breast cancer is complex. Treatment 
guidelines are based on trials including mainly younger patients; elderly patients are 
often excluded. Thus, treatment guidelines are not always generalisable to elderly 
patients. Also, treatment strategies for early breast cancer vary markedly, both 
nationally and internationally. In two recent studies, elderly patient populations from 
European countries were compared (Schuil et al. 2018, Derks et al. 2018). These 
studies found great variance in primary treatment: in the British population, 47.8% 
of patients received surgery in comparison to 90.5% in the Dutch population (Schuil 
et al. 2018). Evidently, older patients have more comorbidities and medications that 
possibly interact with cancer treatment. Several studies report undertreatment of 
elderly patients, and the latest EUSOMA update recognised that that level of 
treatment in elderly patients is partly below the minimum standards of care 
(Biganzoli et al. 2017, Angarita et al. 2015). However, there is strong evidence that a 
more conservative approach to primary surgery and postoperative radiation therapy 
may be adopted in older patients without affecting longer-term outcomes (EBCTCG 
2005b, Tinterri et al. 2014). 
Surgery and survival 
In our elderly population, the surgical treatment rate was high: 90% of patients 
received surgical treatment. Patients receiving surgical treatment had better OS when 
compared with patients without surgical treatment. BCSS was also significantly better 
in surgically treated patients. However, both five-year OS and BCSS are lower than 
Finnish national estimates for all breast cancer patients. The better survival observed 
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in the patients with surgery may also be due to selection bias, at least in part. Patients 
with better physical conditions and therefore also longer life expectancy received 
surgical treatment more often. Accordingly, deaths from any cause during the first 
year of diagnosis were more frequent in patients without surgery, confirming 
successful patient selection when omitting surgical treatment. Moreover, we really do 
not know what the outcome of the patients with surgical treatment would have been if 
treated with endocrine therapy only. In Derks et al. (2018), variation in treatment 
strategies among elderly patients over 70 years of age was found. Interestingly, in 
early stage breast cancer, potential overtreatment was detected. In advanced stages, 
however, potential surgical undertreatment was observed.   
In the present study, the proportion of mastectomies was also high when compared 
to the Study I population. A similar trend towards more extensive procedures in the 
elderly can be seen in previous studies (Sierink et al. 2014, Eaker et al. 2006, Kiderlen 
et al. 2017, van de Water et al. 2014). Mastectomy has adverse effects: an imbalance 
due to the remaining heavy breast can cause functional impairment, postoperative 
seroma formation is more common, and self-evidently, the aesthetic outcome is also 
worse. Aesthetic outcomes after breast cancer surgery may be less important in elderly 
patients, but impairment of functional status should be considered carefully in this 
patient group to avoid negative effects in terms of QoL. Mastectomy was also 
performed to avoid RT after BCS, even though previous studies have clearly shown 
that RT after BCS does not provide a survival benefit but lowers the risk of local 
recurrence also in elderly women (Hughes et al. 2013, EBCTCG 2000, Tinterri et al. 
2009, TInterri et al. 2014, Kunkler et al. 2015, van de Water et al. 2014). For these 
reasons, mastectomy should not be routinely performed, even if RT after breast 
conservation cannot be given due to poor general condition or to patient preference. 
Lately, this was stated in the updated Finnish national guidelines of breast cancer 
treatment and in the EUSOMA treatment recommendation update in 2017 (Biganzoli 
et al. 2017).  
In our study, surgical treatment in elderly patients was safe: there was no 
immediate post-operative mortality.  One-third of the patients in the surgical treatment 
group died within three years of surgery, 35 within the first postoperative year. Most 
of the deaths were from causes other than breast cancer. We can assume these patients 
did not have any survival benefit from surgery and thus may be considered as 
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surgically overtreated. On the other hand, one of the most important aims of breast 
cancer treatment in the elderly is to provide local disease control. Patients may have 
benefited from surgery in terms of local disease control, even though surgery did not 
provide a survival benefit.   
Local disease control  
Primary endocrine treatment instead of surgical treatment has become more common 
during the last decade in the treatment of breast cancer in the elderly (Kiderlen et al. 
2017). If local disease progression during primary endocrine treatment occurs, surgery 
should be reconsidered. However, at the time of local disease progression, the patient 
is older and often also less physically fit than during the time of their primary 
diagnosis. Moreover, for local disease control, a more extensive surgery – mastectomy 
- may be needed. Therefore, local disease progression could seriously affect QoL, 
which is considered of major importance in elderly patients. Our results emphasise 
that local treatment, especially surgery, is the cornerstone of treatment in early breast 
cancer, even among the elderly. Although breast cancer treatment in elderly patients 
may become more conservative, the superior role of primary surgical treatment in 
local control as well as in OS and BCSS should be kept in mind.    
Decision-making 
Breast surgeons and other members of the multidisciplinary team have an 
important role in tailoring the treatment (Angarita et al. 2015, Shumway et al. 2017, 
Morgan et al. 2015). However, evaluating life expectancy even in the presence of 
serious comorbidities is difficult. Functionality and QoL in the elderly may persist at 
the same level for years despite various comorbidities and frailty. It is highly important 
to tailor the treatment of elderly patients on a case-by-case basis, while still aiming for 
the best oncological outcome without sacrificing QoL.  
It is noteworthy that elderly patients are less likely to search for information from 
other sources such as the internet and may rely strongly on their physician’s 
recommendations. Interestingly, in a study by Shumway et al. 2017, nearly half the 
surgeons and radiation oncologists reported that it takes more effort to advise a patient 
that they do not need RT than it does to recommend it. Thus, in fact, a patient’s 
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decision about treatment may actually reflect the physician’s preference and attitude. 
The latest updates on breast cancer treatment recommendations have considered 




10 Limitations of the study 
The major limitation of studies I, III and IV lies in their retrospective, non-randomised 
study setting. Data integration from multiple sources is time-consuming and prone to 
errors, which also delayed the publication of our results. In Study I, we focused on 
factors affecting the quality of surgery and their impacts on waiting times, but not their 
impact on survival and QoL. In Studies III and IV, selection bias due to the 
retrospective, non-randomised setting was detected. In study III, the number of 
patients in the oncoplastic group was small, and some significant associations may 
have remained undetected. The study period also coincided with the beginning of the 
oncoplastic era in our unit, and since then, oncoplastic knowledge and skills of our 
surgeons have improved. Additionally, in Study IV, no geriatric assessment tools were 
used in clinical decision-making. Therefore, a multivariable analysis evaluating the 
influence surgery, tumour characteristics and comorbidities of OS and BCSS could 
not be performed.  
In Study II, the number of study patients was small, especially those who were 
actually discharged on the operation day. The small number of patients may have 
impaired the detection of some differences between the treatment groups. Moreover, 
the questionnaires were designed by the researchers, and validated QoL questionnaires 




The quality of preoperative diagnostics has a great impact on the timely treatment of 
breast cancer. The positive impact of high-volume hospitals became evident in the 
more frequent use of contemporary breast cancer surgeries, such as SNB, IBR and 
oncoplastic resection. 
 
Day surgery is feasible in breast surgery after BCS and SNB.   
 
Overall patient satisfaction after BCS is high. Conventional resection provides good 
or even excellent aesthetic outcomes in correctly selected patients. Oncoplastic 
resection enables BCT in patients with larger and multifocal tumours with a favourable 
aesthetic outcome.   
 
In elderly breast cancer patients, OS and BCSS were better in surgically treated 
patients. Local and regional recurrence rates were low. Surgical treatment was safe in 




This study was conducted at the Breast Surgery Unit of Helsinki University Hospital 
in 2009-2018. 
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Leikatun rinnan ulkonäkö - kyselylomake 
 
 
1. Pyydämme Teitä arvioimaan rintasyöpäleikkauksen esteettistä tulosta eli 





3. Ei hyvä eikä huono 
4. Huono 
5. Erittäin huono 
 
A) Rinnan koko       
   1 2 3 4 5 
B) Nännin sijainti ja ulkonäkö 
1 2 3 4 5 
C) Rinnan muoto ja asento 
   1 2 3 4 5 
D) Leikkausarpi  
   1 2 3 4 5 
E) Rintaliivien istuvuus  
   1 2 3 4 5 
F) Symmetria eli samankaltaisuus toisen rinnan kanssa 
   1 2 3 4 5 
G) Yleisarvosana rinnan ulkonäölle 
   1 2 3 4 5 
 
 
2. Aiheuttaako leikatun rinnan ulkonäkö Teille ongelmia, oletteko esim. joutunut 
luopumaan jostain harrastuksesta, kuten uimahallissa uimisesta tai onko vaikea 
löytää sopivia rintaliivejä 
1) Ei lainkaan ongelmia 
2) Jonkin verran ongelmia 
3) Huomattavia ongelmia 
 
3. Jos leikatun rinnan ulkonäkö aiheuttaa ongelmia, minkälaisia nämä ongelmat ovat? 
       
      
      
      
      
      
   _________________________________ 
